Fernando Perez-Villatoro

Next Friday May 9th I'll be defending my doctoral thesis, about biomarker discovery in #ovariancancer using computational integrative methods. I'm very grateful to all my colleagues, my mentor @afarkkila, @iCAN_Finland and @SystemTumor

It's incredibly rewarding to be part of these research projects and contribute to improving clinical care for #OvCan patients. Read more about my #PhD projects 👇 🖥️#WorldOvarianCancerDay

@TumorBoardTues @afarkkila @IntegrityCE 7/16 #TumorBoardTuesday 🔍Mini Tweetorial 4: Defining HRD tumors🔍 🧬Previous algorithms e.g. Telli2016 combined breast and ovarian samples, hindering precise HRD identification 🔍 #ovaHRDscar: game-changer in HRD detection and patient stratification nature.com/articles/s4169…

@TumorBoardTues @afarkkila @IntegrityCE 8/16 #TumorBoardTuesday 🔍Mini Tweetorial 5: #ovaHRDscar🔍 🔬By @FrandoPV @SystemTumor & team: optimized criteria to identify HGSC HRD tumors beyond BRCAmut 📈#ovaHRDscar is now used for centralized testing of OvCan patients in 🇫🇮 to guide PARPi treatments @HUS_fi @HelsinkiUniMed

Really honored for the opportunity to present our work at the EACR-Cancer-Multiomics-and-Computational-Biology special conference. Thanks @EACRnews, our collaborators and to my mentor @afarkkila

Looking forward to this EACR conference to get to know more interesting advances in the field. I'll be having a short talk presenting part of my PhD work. Eager to brainstorm and exchange ideas with the EACR community.

How can we enhance the utility of models in clinics? This is an excellent article on the subject.

Interested in spatial tumor immunology?Unique opportunity to join our Lab! Please share! jobs.helsinki.fi/job/Helsinki-P… farkkilab.org @HiLIFE_helsinki @FIMM_UH @HelsinkiUniMed @iCAN_Finland

How do #cancer cells with resistant fates differ from the sensitive, already before the treatment? To answer this, we developed ReSisTrace, a cellular time-travel method that uses the similarity of sister cells to trace back pre-existing resistance. nature.com/articles/s4146…

Last night's #Färkkilab pikkujoulu was epic! 🎉 December vibes and a potluck with flavors from around the globe 🌍🍲. A lab that eats together, stays together! 👩‍🔬👨‍🔬

I'm really honored and thrilled to be awarded by The Cancer Society of Finland (@Syopasaatio) the dissertation/incentive grant. Thanks and thanks to my mentor @afarkkila.

@SystemTumor Lab highlighted in flash talks by @FrandoPV and @adajnq 💪🏼#AACRovc23

For this #FluorescenceFriday we bring a trhowback to one of our iconic serial killer T cells in honor of all the great work performed on understanding and enhancing T cell #immunotherapy using #LiveCellImaging for #CancerResearch

I think we need to talk about how devastating this cancer microbiome refutation paper from @StevenSalzberg1 and colleagues is. It really speaks to how devoid of critical thinking and intellectual depth our glam publishing ecosystem has become. 1/n biorxiv.org/content/10.110…

Congrats @FrandoPV for great talk at the #rpuscienceday2023 #oncosys #ovariancancer #CancerResearch

Excited to start #EASimmuneresponses With @Dr_Alfredo_ @FrandoPV and Ashwini presenting our work!

Our work highlighted in the Finnish tabloid #iltalehti! Glad to see promotion of #ovariancancer awareness and information on PARP inhibitors to the public and #patients @Syopapotilaat @iCAN_Finland

@afarkkila Our original article is available here: doi.org/10.1038/s41698…

My behind the paper -blog post titled "Ovarian cancer specific homologous recombination deficiency score" is available here: go.nature.com/3Gw2j8r Check the description and relevance of our latest article. Thanks @afarkkila and all collaborators for the support.

I am happy to share our recent work on an optimized HRD test for #ovarian cancer! Importantly, #ovaHRDscar is already implemented into the clinics @HUS_fi as basis for treatment with PARP inhibitors. @HelsinkiUniMed @nsgo_org nature.com/articles/s4169…